Pustular Psoriasis and Associated Musculoskeletal Disorders

2021 ◽  
pp. jrheum.201673
Author(s):  
Kristina Callis Duffin ◽  
Hervé Bachelez ◽  
Philip J. Mease ◽  
Cheryl Rosen ◽  
Amit Garg ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Musculoskeletal Disorders ◽  
Systemic Inflammation ◽  
Pustular Psoriasis ◽  
Sapho Syndrome ◽  
Palmoplantar Pustulosis ◽  
Targeted Drug ◽  
Targeted Drug Therapies ◽  
Chronic Nonbacterial Osteomyelitis

Pustular psoriasis (PsO) is an uncommon variant of PsO that may present in a generalized or localized fashion with or without musculoskeletal or systemic inflammatory involvement. Generalized pustular PsO (GPP) presents as a widespread acute or subacute pustular eruption that may be familial and is often associated with severe flares and systemic inflammation. The palmoplantar pustulosis variant is localized to palms and soles, whereas acrodermatitis continua of Hallopeau is localized to the nail apparatus. Patients with pustular PsO may have overlapping plaque PsO and may develop psoriatic arthritis (PsA). Pustulosis is also a feature of both synovitis, acne, pustulosis, hyperostosis, osteomyelitis (SAPHO) syndrome and chronic nonbacterial osteomyelitis. At the 2020 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting, members were given an overview of the cutaneous features of pustular PsO, SAPHO, and recent insights into the genetics of GPP, leading to new targeted drug therapies and the development of validated endpoints.

scholarly journals Apremilast monotherapy for palmoplantar pustulosis: Report of three cases

2021 ◽  
Vol 9 ◽  
pp. 2050313X2110349
Author(s):  
Maruška Marovt ◽  
Pij B Marko
Keyword(s):  
Psoriatic Arthritis ◽  
Pustular Psoriasis ◽  
Quality Data ◽  
Palmoplantar Pustulosis ◽  
High Quality ◽  
High Quality Data ◽  
Phosphodiesterase 4 ◽  
Molecule Inhibitor ◽  
Chronic Skin ◽  
Skin Conditions

Palmoplantar pustulosis or palmoplantar pustular psoriasis is chronic skin conditions, characterised by eruptions of sterile pustules on an erythematosquamous background. High-quality data on the treatment of palmoplantar pustulosis are limited, and none is accepted as being effective in general. Apremilast is a small molecule inhibitor of phosphodiesterase 4 approved for the treatment of plaque psoriasis and psoriatic arthritis. We report three cases of palmoplantar pustulosis treated with apremilast monotherapy. Our three cases, as well as previous reports, demonstrate the potential for apremilast to be beneficial for a subset of patients with palmoplantar pustulosis or palmoplantar pustular psoriasis.

Prologue: 2020 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

2021 ◽  
pp. jrheum.201666
Author(s):  
Kristina Callis Duffin ◽  
Alice B. Gottlieb ◽  
Denis O’Sullivan ◽  
Dafna D. Gladman ◽  
Lynne V. McFarland
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Outcome Measures ◽  
Treatment Guidelines ◽  
Clinical Care ◽  
Pustular Psoriasis ◽  
Research Network ◽  
Grant Writing ◽  
Psoriatic Disease ◽  
Travel Restrictions

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) held its annual meeting in 2020 in an online format due to travel restrictions during the coronavirus disease 2019 (COVID‑19; caused by SARS-CoV-2) pandemic. The virtual meeting was attended by 351 rheumatologists, dermatologists, representatives of biopharmaceutical companies, and patient research partners. Similar to previous years, GRAPPA’s annual meeting focused on the 3 overlapping missions of education, research, and clinical care of psoriatic disease. Trainee sessions this year included the annual trainee symposium and a grant-writing workshop. Plenary sessions included updates on COVID-19 and psoriatic disease from multispecialty and patient perspectives, and updates on pustular psoriasis and associated musculoskeletal manifestations. Progress on research and updates were presented for the following groups: Collaborative Research Network, Outcome Measures in Rheumatology (OMERACT) Psoriatic Arthritis Working Group, International Dermatology Outcome Measures, Composite Measures, Education Committee, and Treatment Guidelines. New this year were 3 concurrent workshops on ultrasound assessment of joints and entheses, magnetic resonance imaging of psoriatic arthritis, and pustular psoriasis efficacy endpoints; 6 “Meet the Expert” sessions; and facilitated “poster tours.” In our prologue, we introduce the papers that summarize this meeting.

Generalized pustular psoriasis-like eruptions induced after the first use of adalimumab in the treatment of psoriatic arthritis

2011 ◽  
Vol 39 (3) ◽  
pp. 286-287 ◽  
Author(s):  
Utako KIMURA ◽  
Ayako KINOSHITA ◽  
Kunitaka HARUNA ◽  
Yuki MIZUNO ◽  
Iwao SEKIGAWA ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Pustular Psoriasis ◽  
Generalized Pustular Psoriasis

Cardiovascular Comorbidities of Psoriasis and Psoriatic Arthritis: A Report from the GRAPPA 2012 Annual Meeting

2013 ◽  
Vol 40 (8) ◽  
pp. 1434-1437 ◽  
Author(s):  
April W. Armstrong ◽  
Joel M. Gelfand ◽  
Wolf-Henning Boehncke ◽  
Ehrin J. Armstrong
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Tumor Necrosis ◽  
Panel Discussion ◽  
Future Research ◽  
Research Directions ◽  
Cardiovascular Comorbidities ◽  
Future Research Directions ◽  
Necrosis Factor

At the 2012 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) in Stockholm, Sweden, several GRAPPA members led a panel discussion on cardiovascular (CV) comorbidities of psoriasis and psoriatic arthritis (PsA). The panelists discussed the role of insulin resistance in the pathophysiology of psoriasis, the possible effect of tumor necrosis factor inhibitors on CV comorbidities, and the effect of 12/23 monoclonal antibodies on CV outcomes. The panelists also addressed how lessons from CV comorbidity research could be applied to other areas of comorbidity research in psoriasis and PsA and identified future research directions in this area.

scholarly journals Magnetic Resonance Imaging in Psoriatic Arthritis — Update on Current Status and Future Perspectives: A Report from the GRAPPA 2010 Annual Meeting

2012 ◽  
Vol 39 (2) ◽  
pp. 408-412 ◽  
Author(s):  
MIKKEL ØSTERGAARD ◽  
RENÉ PANDURO POGGENBORG
Keyword(s):  
Magnetic Resonance Imaging ◽  
Psoriatic Arthritis ◽  
Magnetic Resonance ◽  
Annual Meeting ◽  
Current Status ◽  
Future Research ◽  
Future Perspectives ◽  
Resonance Imaging ◽  
Primary Driver ◽  
Magnetic Resonance Imaging Mri

The potential of magnetic resonance imaging (MRI) for use in clinical practice and research has gained increasing interest over the last decade. International collaborative initiatives from GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) and/or OMERACT (Outcome Measures in Rheumatology) may contribute to facilitating research, identifying appropriate areas for use, and reaching consensus on the optimal examination technique. Accordingly, GRAPPA, a primary driver of international research in psoriasis and psoriatic arthritis (PsA), has focused on the current use and future development of MRI and other modern imaging modalities in PsA. This review, presented at the GRAPPA 2010 annual meeting, describes the current status of MRI in PsA, with a focus on its use in diagnosis, monitoring, and prediction of the disease course and treatment response. Important areas for future research are also outlined.

Biomarkers of Radiographic Progression in Psoriatic Arthritis: A Report from the GRAPPA 2011 Annual Meeting

2012 ◽  
Vol 39 (11) ◽  
pp. 2189-2192 ◽  
Author(s):  
OLIVER FITZGERALD ◽  
CHRISTOPHER T. RITCHLIN ◽  
PHILIP J. MEASE
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Structural Damage ◽  
Radiographic Progression ◽  
Clinical Markers ◽  
Sample Collection ◽  
Critical Research ◽  
Specific Protocol ◽  
Radiographic Scoring Methods ◽  
Selection Of

Clinical markers of radiographic progression have been studied in patients with psoriatic arthritis (PsA), and results have clearly confirmed the progression of radiographic damage over a 2-year period. Biomarkers of radiographic progression damage (erosion and new bone formation) have also been identified as a critical research issue in these patients. At the 2011 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members discussed development of a pivotal observational study (PsA Biodam study) to determine the validity of several soluble biomarkers in predicting structural damage in patients with PsA receiving standard therapies. Specific protocol issues discussed were the inclusion criteria, selection of candidate biomarkers, timing of sample collection, the primary radiographic outcome measure, radiographic scoring methods, possible substudies, and funding strategies.

scholarly journals Using Acute-phase Reactants to Inform the Development of Instruments for the Updated Psoriatic Arthritis Core Outcome Measurement Set

2018 ◽  
Vol 46 (3) ◽  
pp. 266-273 ◽  
Author(s):  
Musaab Elmamoun ◽  
Ying Ying Leung ◽  
Denis O’Sullivan ◽  
Ingrid Steinkoenig ◽  
Vinod Chandran ◽  
...  
Keyword(s):  
Systematic Review ◽  
Psoriatic Arthritis ◽  
Construct Validity ◽  
Acute Phase ◽  
Systemic Inflammation ◽  
Outcome Measurement ◽  
Cardiovascular Outcomes ◽  
Inflammatory Biomarkers ◽  
Response Criteria ◽  
Acute Phase Reactants

Objective.Systemic inflammationˆ is assessed through measurement of acute-phase reactants such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). With few exceptions, most randomized controlled trials (RCT) have assessed acute-phase reactants (CRP and ESR) as part of the American College of Rheumatology (ACR) 20 response criteria. As part of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)–Outcome Measures in Rheumatology (OMERACT) working group, we performed a systematic review of the literature to assess the performance of inflammatory biomarkers in psoriatic arthritis (PsA).Methods.A systematic search of PubMed and Embase was performed. The search included peer-reviewed articles and scientific meeting abstracts about RCT and longitudinal observational studies that assessed systemic inflammation using acute-phase reactants in PsA. Studies were assessed following the components of the OMERACT filter including construct validity, responsiveness, and predictive validity.Results.There were 2764 articles retrieved, and 71 articles were included for this systematic review. Twenty-eight articles reported CRP and/or ESR separately, and the remaining articles reported CRP and/or ESR as part of the ACR response criteria. Studies assessing OMERACT responsiveness provided conflicting reports. Inflammatory biomarkers had construct validity for more active disease. Evidence suggests that an elevation of ESR predicts cardiovascular outcomes.Conclusion.Data regarding assessment of systemic inflammation using acute-phase reactants (CRP and ESR) are limited. There is only weak evidence to support normalization of these biomarkers in predicting good clinical outcomes/remission criteria. The predictive value for cardiovascular outcomes was generally good. Further studies to assess systemic inflammation in PsA using acute-phase reactants and other laboratory biomarkers are needed.

Sign in / Sign up

Export Citation Format

Share Document